Compare HLIO & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLIO | RAPP |
|---|---|---|
| Founded | 1970 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 1996 | 2024 |
| Metric | HLIO | RAPP |
|---|---|---|
| Price | $68.66 | $41.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $66.17 | $48.50 |
| AVG Volume (30 Days) | 253.2K | ★ 292.3K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | 23.93 | ★ 24.34 |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $200,727,000.00 | N/A |
| Revenue This Year | $3.67 | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | $54.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $47.05 | $23.75 |
| 52 Week High | $95.05 | $52.93 |
| Indicator | HLIO | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 40.24 | 27.77 |
| Support Level | $65.83 | $33.54 |
| Resistance Level | $76.32 | $40.61 |
| Average True Range (ATR) | 1.92 | 2.15 |
| MACD | 0.16 | -0.96 |
| Stochastic Oscillator | 38.50 | 0.82 |
Helios Technologies Inc is an industrial technology company that develops, manufactures, and markets solutions for the hydraulics and electronics markets. It operates under two business segments: Hydraulics and Electronics. The Hydraulics segment designs and manufactures hydraulic components and systems used to transmit power and control force, speed, and motion. There are two categories based on Hydraulic system architecture: MCT and FCT. The Electronics segment provides complete, fully-tailored display and control solutions for engines, engine-driven equipment, specialty vehicles, therapy baths, and traditional and swim spas. The company generates the majority of its revenue from the Hydraulics segment. Geographically, the company generates key revenue from the Americas region.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.